These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 29277810)
1. CEA, CA 15-3, and TPS as Prognostic Factors in the Follow-up Monitoring of Patients After Radical Surgery for Breast Cancer. Svobodova S; Kucera R; Fiala O; Karlikova M; Narsanska A; Zedníková I; Treska V; Slouka D; Rousarova M; Topolcan O; Finek J Anticancer Res; 2018 Jan; 38(1):465-469. PubMed ID: 29277810 [TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up. Samy N; Ragab HM; El Maksoud NA; Shaalan M Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232 [TBL] [Abstract][Full Text] [Related]
3. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854 [TBL] [Abstract][Full Text] [Related]
4. Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancer. D'Alessandro R; Roselli M; Ferroni P; Mariotti S; Spila A; Aloe S; Carone MD; Abbolito MR; Carlini S; Perri P; Ricciotti A; Botti C; Conti F; Vici P; Chiappetta NR; Cognetti F; Buonomo O; Guadagni F Breast Cancer Res Treat; 2001 Jul; 68(1):9-19. PubMed ID: 11678313 [TBL] [Abstract][Full Text] [Related]
5. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse. Vizcarra E; Lluch A; Cibrián R; Jarque F; García-Conde J Oncology; 1994; 51(6):491-6. PubMed ID: 7970492 [TBL] [Abstract][Full Text] [Related]
6. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients. Hu XC; Day W; Jones B; Loo WT; Chow LW Anticancer Res; 2002; 22(3):1865-8. PubMed ID: 12168883 [TBL] [Abstract][Full Text] [Related]
7. Plasma cell-free DNA chromosomal instability analysis by low-pass whole-genome sequencing to monitor breast cancer relapse. Zhou H; Wang XJ; Jiang X; Qian Z; Chen T; Hu Y; Chen ZH; Gao Y; Wang R; Ye WW; Cao WM Breast Cancer Res Treat; 2019 Nov; 178(1):63-73. PubMed ID: 31364001 [TBL] [Abstract][Full Text] [Related]
8. Periodic measurement of serum carcinoembryonic antigen and carbohydrate antigen 15-3 levels as postoperative surveillance after breast cancer surgery. Nakamura T; Kimura T; Umehara Y; Suzuki K; Okamoto K; Okumura T; Morizumi S; Kawabata T Surg Today; 2005; 35(1):19-21. PubMed ID: 15622458 [TBL] [Abstract][Full Text] [Related]
9. Elevated serum CA15-3 levels correlate with positive estrogen receptor and initial favorable outcome in patients who died from recurrent breast cancer. Nishimura R; Nagao K; Miyayama H; Matsuda M; Baba K; Matsuoka Y; Yamashita H Breast Cancer; 2003; 10(3):220-7. PubMed ID: 12955034 [TBL] [Abstract][Full Text] [Related]
10. Sensitivity of serum tumor markers CEA and CA 15-3 in breast cancer recurrences and correlation with different prognostic factors. Lumachi F; Brandes AA; Ermani M; Bruno G; Boccagni P Anticancer Res; 2000; 20(6C):4751-5. PubMed ID: 11205212 [TBL] [Abstract][Full Text] [Related]
11. The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer. Zhang J; Wei Q; Dong D; Ren L Clin Chim Acta; 2021 Dec; 523():19-25. PubMed ID: 34454906 [TBL] [Abstract][Full Text] [Related]
12. [Clinical and prognostic significance of preoperative serum CA153, CEA and TPS levels in patients with primary breast cancer]. Chen Y; Zheng YH; Lin YY; Hu MH; Chen YS Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):842-6. PubMed ID: 22335950 [TBL] [Abstract][Full Text] [Related]
13. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes. Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K J BUON; 2013; 18(3):608-13. PubMed ID: 24065471 [TBL] [Abstract][Full Text] [Related]
14. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA). Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221 [TBL] [Abstract][Full Text] [Related]
15. Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer. Pedersen AC; Sørensen PD; Jacobsen EH; Madsen JS; Brandslund I Clin Chem Lab Med; 2013 Jul; 51(7):1511-9. PubMed ID: 23403727 [TBL] [Abstract][Full Text] [Related]
16. Serum tumour markers CEA, AFP, CA 15-3, TPS and Neu in diagnosis of breast cancer. Eskelinen M; Kataja V; Hämäläinen E; Kosma VM; Penttilä I; Alhava E Anticancer Res; 1997; 17(2B):1231-4. PubMed ID: 9137478 [TBL] [Abstract][Full Text] [Related]
17. Circulating CA 15-3 levels in the postsurgical follow-up of breast cancer patients and in non-malignant diseases. Colomer R; Ruibal A; Genollá J; Rubio D; Del Campo JM; Bodi R; Salvador L Breast Cancer Res Treat; 1989 Mar; 13(2):123-33. PubMed ID: 2730960 [TBL] [Abstract][Full Text] [Related]
18. [CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3]. Riedinger JM; Goussot V; Desmoulins I; Lorgis V; Coutant C; Beltjens F; Lizard S; Fumoleau P Bull Cancer; 2016 May; 103(5):434-43. PubMed ID: 26969424 [TBL] [Abstract][Full Text] [Related]
19. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3. Di Gioia D; Blankenburg I; Nagel D; Heinemann V; Stieber P Clin Chim Acta; 2016 Oct; 461():1-7. PubMed ID: 27451906 [TBL] [Abstract][Full Text] [Related]
20. Relationship between preoperative serum markers CA 15-3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer. Lumachi F; Basso SM; Bonamini M; Marzano B; Milan E; Waclaw BU; Chiara GB Anticancer Res; 2010 Jun; 30(6):2331-4. PubMed ID: 20651388 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]